StockData
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. (XRTX) stock

XRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 0/30
$1.06+0.02 (+1.92%)

Close on Nov 17, 2026Market cap $116.17KP/E –Yield –

XORTX Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2021 it was C$853.12K, up 207.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2021Dec 31, 2021C$853.12K+207.5%
FY2020Dec 31, 2020C$277.46K+595.4%
FY2019Dec 31, 2019C$39.90K–

More XORTX Therapeutics figures

See a number that looks wrong?